• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伏格特-小柳-原田病:在瑞士和日本的历史背景下探究一种疾病名称的起源

Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.

作者信息

Herbort Carl P, Mochizuki Manabu

机构信息

Inflammatory and Retinal Eye Diseases, Centre for Ophthalmic Specialized Care (COS), La Source Avenue des Bergières 2, Lausanne 1004, Switzerland.

出版信息

Int Ophthalmol. 2007 Apr-Jun;27(2-3):67-79. doi: 10.1007/s10792-007-9083-4. Epub 2007 Apr 28.

DOI:10.1007/s10792-007-9083-4
PMID:17468832
Abstract

PURPOSE

To delineate the historical steps associated with the genesis of the name and the definition of Vogt-Koyanagi-Harada (VKH) disease.

METHODS

A bibliographical review of the major publications that were relevant to the original development of the name of the clinical entity known today as Vogt-Koyanagi-Harada disease, in the historical context of the early 20th century.

RESULTS

Three distinct time periods can be considered to be important in terms of providing a historical perspective on VKH disease. Given that the cutaneous manifestations of VKH disease are so characteristic, these could not have been missed even before the actual clinical entity of VKH was recognized in the early 20th century. Indeed, several authors, including the Arabic doctor Mohammad-al-Ghâfiqî in the 12th century as well as Jacobi, Nettelship and Tay in the 19th century, described poliosis, neuralgias and hearing disorders. Many of these cases were probably due to sympathetic ophthalmia, but some were clearly VKH cases. The second phase is characterized by the surge of articles that appeared early in the 20th century that defined the disease more precisely. A number of these authors subsequently became associated with the disease name, the first being Alfred Vogt from Switzerland, followed by Japanese researchers. Yoshizo Koyanagi was in fact not the first Japanese author to describe the disease; this honor goes to the first Japanese Professor of Ophthalmology at the University of Tokyo, Dr. Jujiro Komoto, who published in a German language journal, Klinische Monatsblätter für Augenheilkunde in 1911. Yoshizo Koyanagi published his first report in the Nippon Ganka Gakkai Zasshi 3 years later, in 1914, but it was a much later article, one published in 1929, that definitively associated his name with the disease. In this review article, Koyanagi reported 16 cases, of which six were his own cases, that beautifully illustrate the natural course of the disease. In this same time period, Einosuke Harada, in an article published in Nippon Ganka Gakkai Zasshi in 1926 that was based on several case studies, comprehensively described a syndrome that included (1) a prodromal phase of malaise and meningeal irritation; (2) bilateral uveitis of diverse intensity; (3) bilateral retinal detachments spontaneously resolving; (4) integumentary changes; (5) lymphocytosis of the spinal fluid; (6) dysacousia. It is now accepted that Vogt-Koyanagi disease and the syndrome described by Harada are one entity with a diverse clinical spectrum bearing the universally accepted name of Vogt-Koyanagi-Harada disease. The third phase and most recent phase is characterized by the rapid progress made in terms of knowledge of the physiopathology of the disease, primarily due to the development of immunological methods. The evidence accumulated to date clearly points towards an autoimmune Th1 disease directed against proteins associated with choroidal melanin. Other analytical techniques, such as indocyanine green angiography, have enabled researchers to monitor more closely the primary lesional process at the level of the choroid, and standardized diagnostic criteria have been generated in the recent past.

CONCLUSION

Those who earn scientific merit in clinical medicine are the ones who are able to visualize an overview based on the synthesis of 'new' medical facts that have been made available, usually reported singly by several, unassociated authors concomitantly. This is certainly the case for Yoshizo Koyanagi and Einosuke Harada. Conversely, Alfred Vogt was primarily lucky in that he encountered and subsequently precisely described the first case in the literature.

摘要

目的

阐述与伏格特-小柳-原田(VKH)病名称起源及定义相关的历史进程。

方法

在20世纪初的历史背景下,对与现今被称为VKH病这一临床实体名称最初发展相关的主要出版物进行文献综述。

结果

就提供VKH病的历史视角而言,可认为有三个不同的时期很重要。鉴于VKH病的皮肤表现非常具有特征性,即使在20世纪初VKH病的实际临床实体被认识之前,这些表现也不可能被忽视。事实上,包括12世纪的阿拉伯医生穆罕默德 - 阿尔 - 加菲基以及19世纪的雅各比、内特尔希普和泰在内的几位作者,都描述过白发症、神经痛和听力障碍。这些病例中的许多可能是交感性眼炎,但有些显然是VKH病病例。第二个阶段的特点是20世纪初出现了大量更精确界定该病的文章。这些作者中有许多后来与该病名联系在一起,首先是来自瑞士的阿尔弗雷德·伏格特,随后是日本研究人员。事实上,小柳义三并非第一位描述该病的日本作者;这一荣誉属于东京大学第一位眼科教授小本重次郎博士,他于1911年在德语期刊《眼科临床月刊》上发表了相关文章。小柳义三3年后,即1914年,在《日本眼科学会杂志》上发表了他的第一篇报告,但直到1929年发表的一篇更晚的文章才最终将他的名字与该病联系起来。在这篇综述文章中,小柳报告了16例病例,其中6例是他自己的病例,这些病例很好地说明了该病的自然病程。在同一时期,原田荣之助在1926年发表于《日本眼科学会杂志》的一篇基于多个病例研究的文章中,全面描述了一种综合征,包括:(1)前驱期的不适和脑膜刺激症状;(2)不同程度的双侧葡萄膜炎;(3)双侧视网膜脱离自发缓解;(4)皮肤改变;(5)脑脊液淋巴细胞增多;(6)听力障碍。现在人们公认伏格特 - 小柳病和原田描述的综合征是同一实体,具有广泛的临床谱,通用名称为伏格特 - 小柳 - 原田病。第三个也是最近的阶段的特点是在该病的生理病理学知识方面取得了快速进展,这主要归功于免疫学方法的发展。迄今为止积累的证据明确指向一种针对与脉络膜黑色素相关蛋白质的自身免疫性Th1疾病。其他分析技术,如吲哚菁绿血管造影术,使研究人员能够更密切地监测脉络膜水平的原发性病变过程,并且最近已经制定了标准化的诊断标准。

结论

在临床医学中获得科学功绩的人是那些能够基于对通常由几位不相关作者单独报告的“新”医学事实进行综合而形成总体认识的人。小柳义三和平田荣之助肯定就是这种情况。相反,阿尔弗雷德·伏格特主要是运气好,因为他遇到并随后精确描述了文献中的首例病例。

相似文献

1
Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.伏格特-小柳-原田病:在瑞士和日本的历史背景下探究一种疾病名称的起源
Int Ophthalmol. 2007 Apr-Jun;27(2-3):67-79. doi: 10.1007/s10792-007-9083-4. Epub 2007 Apr 28.
2
Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.白癜风作为 Vogt-Koyanagi-Harada 病的首发症状。
Acta Dermatovenerol Croat. 2023 Dec;31(4):229-231.
3
Vogt-Koyanagi-Harada Syndrome伏格特-小柳-原田综合征
4
Vogt-koyanagi-harada syndrome.伏格特-小柳-原田综合征
Curr Eye Res. 2008 Jul;33(7):517-23. doi: 10.1080/02713680802233968.
5
[Vogt-Koyanagi-Harada syndrome: importance of rapid diagnosis and therapeutic intervention].[伏格特-小柳-原田综合征:快速诊断和治疗干预的重要性]
Klin Monbl Augenheilkd. 2000 May;216(5):290-4. doi: 10.1055/s-2000-10987.
6
Vogt-Koyanagi-Harada disease.伏格特-小柳-原田病
Surv Ophthalmol. 2017 Jan-Feb;62(1):1-25. doi: 10.1016/j.survophthal.2016.05.002. Epub 2016 May 27.
7
Diagnosis and classification of Vogt-Koyanagi-Harada disease.Vogt-小柳原田病的诊断和分类。
Autoimmun Rev. 2014 Apr-May;13(4-5):550-5. doi: 10.1016/j.autrev.2014.01.023. Epub 2014 Jan 15.
8
[A rare case of ocular scarrings in a patient with Vogt-Koyanagi-Harada disease].[1例Vogt-小柳-原田病患者眼部瘢痕形成的罕见病例]
Pan Afr Med J. 2017 Dec 22;28:313. doi: 10.11604/pamj.2017.28.313.4547. eCollection 2017.
9
Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.中国患者交感性眼炎与 Vogt-小柳原田病的临床特征和视力预后比较。
Ophthalmology. 2019 Sep;126(9):1297-1305. doi: 10.1016/j.ophtha.2019.03.049. Epub 2019 Apr 6.
10
New insights into Vogt-Koyanagi-Harada disease.小柳原田病的新见解
Arq Bras Oftalmol. 2009 May-Jun;72(3):413-20. doi: 10.1590/s0004-27492009000300028.

引用本文的文献

1
Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease.脉冲式与半脉冲式类固醇疗法治疗Vogt-小柳-原田病的疗效与安全性比较研究
Jpn J Ophthalmol. 2025 May 26. doi: 10.1007/s10384-025-01213-3.
2
Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature.帕博利珠单抗继发于转移性胃癌的类伏格特-小柳-原田葡萄膜炎:一例报告及文献复习
Case Rep Oncol. 2024 Sep 25;17(1):1071-1086. doi: 10.1159/000541133. eCollection 2024 Jan-Dec.
3
Ultrasonographic study of the orbit as an early diagnostic tool in Vogt Koyanagi Harada disease (VKH): A case report.

本文引用的文献

1
Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.吲哚菁绿血管造影在Vogt-小柳-原田病中的应用:血管造影征象及在患者随访中的作用
Int Ophthalmol. 2007 Apr-Jun;27(2-3):173-82. doi: 10.1007/s10792-007-9060-y. Epub 2007 Apr 25.
2
Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.葡萄膜大脑炎患者的眼部浸润性CD4 + T细胞可识别人类黑素细胞抗原。
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2547-54. doi: 10.1167/iovs.05-1547.
3
[Vogt-Koyanagi-Harada syndrome--historical changes in the eponym].
超声检查眼眶作为Vogt-小柳-原田病(VKH)早期诊断工具的研究:一例报告
Heliyon. 2024 Feb 10;10(4):e26196. doi: 10.1016/j.heliyon.2024.e26196. eCollection 2024 Feb 29.
4
Classification of Peripheral Blood Leukocyte Phenotypes and Serum Cytokines in Vogt-Koyanagi-Harada Disease before and after Glucocorticoid Therapy.糖皮质激素治疗前后葡萄膜炎-白癜风-脱发-耳鸣综合征患者外周血白细胞表型及血清细胞因子的分类
J Clin Med. 2023 Dec 17;12(24):7742. doi: 10.3390/jcm12247742.
5
Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.伏格特-小柳-原田病的免疫抑制治疗:一项回顾性研究及文献综述
J Ophthalmic Inflamm Infect. 2023 May 19;13(1):27. doi: 10.1186/s12348-023-00333-6.
6
Persistent Macular Edema in a Pediatric Vogt-Koyanagi-Harada Disease Patient: A Case Report.一名小儿Vogt-小柳-原田病患者的持续性黄斑水肿:病例报告
Cureus. 2022 Sep 26;14(9):e29635. doi: 10.7759/cureus.29635. eCollection 2022 Sep.
7
Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review.伏格特-小柳-原田病:逐步深入了解临床病理学、免疫病理学、诊断及管理的方法:简要综述
J Ophthalmic Inflamm Infect. 2022 May 12;12(1):17. doi: 10.1186/s12348-022-00293-3.
8
Vogt-Koyanagi-Harada Syndrome - A Neurologist's Perspective.伏格特-小柳-原田综合征——一位神经科医生的观点
Ann Indian Acad Neurol. 2021 May-Jun;24(3):405-409. doi: 10.4103/aian.AIAN_405_20. Epub 2020 Jul 31.
9
Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.初发性 Vogt-小柳-原田病的精确简化诊断标准和优化管理:最新综述。
Eye (Lond). 2022 Jan;36(1):29-43. doi: 10.1038/s41433-021-01573-3. Epub 2021 Jun 18.
10
Correlation between Subfoveal Choroidal Thickness and Anterior Segment Inflammation in Patients with Chronic Stage of Vogt-Koyanagi-Harada Disease.Vogt-小柳原田病慢性期患者的脉络膜中心凹下厚度与前节炎症的相关性。
Ocul Immunol Inflamm. 2022 Apr 3;30(3):646-651. doi: 10.1080/09273948.2020.1826533. Epub 2020 Oct 6.
[伏格特-小柳-原田综合征——该疾病名称的历史变迁]
Nippon Ganka Gakkai Zasshi. 2006 Feb;110(2):144-9.
4
T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.HLA-DRB1*0405阳性和阴性伏格特-小柳-原田葡萄膜炎患者中黑素细胞表位诱导的T细胞识别和细胞因子谱
Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2465-71. doi: 10.1167/iovs.04-1273.
5
Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease.Vogt-小柳原田病中自身反应性T细胞的鉴定。
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2004-9.
6
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.Vogt-小柳-原田病修订诊断标准:国际命名委员会报告
Am J Ophthalmol. 2001 May;131(5):647-52. doi: 10.1016/s0002-9394(01)00925-4.
7
The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease.吲哚青绿血管造影在Vogt-小柳-原田病评估与治疗中的作用。
Ophthalmology. 2001 Jan;108(1):54-64. doi: 10.1016/s0161-6420(00)00428-0.
8
Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease.酪氨酸酶家族蛋白是小柳原田病特有的抗原。
J Immunol. 2000 Dec 15;165(12):7323-9. doi: 10.4049/jimmunol.165.12.7323.
9
Vogt-Koyanagi-Harada syndrome after cutaneous injury.皮肤损伤后发生的小柳原田综合征。
Ophthalmology. 1999 Mar;106(3):635-8. doi: 10.1016/S0161-6420(99)90129-X.
10
Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient.来自一位小柳原田病患者的 HLA-DR 限制性 T 细胞系所识别的酪氨酸酶表位。
Immunogenetics. 1998 Apr;47(5):398-403. doi: 10.1007/s002510050375.